Binimetinib (MEK162, ARRY-162) is a MEK inhibitor being developed by Array Biopharma to treat various cancers.
It can be taken orally in tablet form.
In 2015 it was in phase 3 clinical trials for ovarian cancer, BRAF mutant melanoma, and NRAS Q61 mutant melanoma.
In Dec 2015 the company announced that the mutant-NRAS melanoma trial was successful. In the trial, those receiving binimetinib had a median progression-free survival of 2.8 months versus 1.5 months for those on the standard dacarbazine treatment. NDA submitted Jun 2016.
In April 2016 it was reported that the phase III trial for low-grade ovarian cancer was terminated due to lack of efficacy.

基本信息